Key Takeaways:
- Johnson & Johnson's revenue surged to $88.8 billion in 2024, marking a 4.3% increase.
- The acquisition of IntraCellular Therapeutics strengthens its portfolio, adding the promising Caplyta treatment.
- Analysts maintain favorable ratings, reflecting strong growth potential for JNJ.
Johnson & Johnson's Revenue Growth and Strategic Acquisition
In an impressive stride during 2024, Johnson & Johnson (JNJ, Financial) reported a 4.3% boost in revenue, achieving a remarkable $88.8 billion. A significant highlight this year includes the strategic acquisition of IntraCellular Therapeutics for $14.6 billion, enhancing JNJ's portfolio with Caplyta—a cutting-edge treatment targeting mental health disorders. This acquisition underscores the company's commitment to diversifying and expanding its therapeutic offerings.
Wall Street Analysts Forecast for JNJ
With 24 analysts providing insights into Johnson & Johnson's future, the average one-year price target stands at $170.72. This suggests a potential upside of 8.42% from its current trading price of $157.47. Price projections range from a conservative low of $150.00 to an optimistic high of $185.00. Further insights and target data are available on the Johnson & Johnson (JNJ, Financial) Forecast page.
Brokerage Recommendations Reflect Outperform Expectations
Among 26 brokerage firms, the consensus recommendation for Johnson & Johnson remains robust, with an average score of 2.3, categorizing the stock as "Outperform." This rating is based on a scale from 1 to 5, where 1 equates to a Strong Buy, and 5 signals a Sell. Such strong consensus highlights the enduring confidence in JNJ's market performance and strategic direction.
Assessing GF Value and Future Potential
According to GuruFocus estimates, the projected GF Value for Johnson & Johnson in the next year is $188.29. This estimation indicates a potential upside of 19.57% from its current share price of $157.47. The GF Value represents GuruFocus' calculation of the fair trading value of the stock, derived from historical trading multiples, past business growth, and anticipated future performance metrics. Detailed data and analyses are available on the Johnson & Johnson (JNJ, Financial) Summary page.
